A case report of a multi-drug resistant bacterial infection in a diabetic patient treated in northeast Brazil

Diabetic Foot and Ankle

Volumn 3, Issue , 2012, Pages 1-6

  Neto, Renato Motta ^a   Ansaldi, Miguel Angel ^a   da Costa, Maria Eduarda S M ^a   da Silva, Samuel Oliveira ^a   Luz, Victor Hugo F ^a  

^a FEDERAL UNIVERSITY OF RIO GRANDE DO NORTE   (Brazil)

Author keywords

Diabetic foot; Neuropathy; Polymicrobial infection; Resistance; Ulcer

Indexed keywords

CEFEPIME; CEFOXITIN; CEFTRIAXONE; CHLORAMPHENICOL; CIPROFLOXACIN; CLINDAMYCIN; COTRIMOXAZOLE; ERYTHROMYCIN; GENTAMICIN; GLUCOSE; IMIPENEM; MEROPENEM; OXACILLIN; PIPERACILLIN PLUS TAZOBACTAM; RIFAMPICIN; TETRACYCLINE; TIGECYCLINE; VANCOMYCIN;

ACINETOBACTER BAUMANNII; ACINETOBACTER LWOFFII; AGED; ANKLE INJURY; ANTIBIOTIC RESISTANCE; BACTERIAL INFECTION; BACTERIUM CULTURE; BRAZIL; CASE REPORT; DEBRIDEMENT; DIABETES MELLITUS; DIABETIC FOOT; DIABETIC PATIENT; DISK DIFFUSION; GLUCOSE BLOOD LEVEL; HUMAN; INFECTION COMPLICATION; LEG AMPUTATION; MALE; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; NONHUMAN; OSTEOMYELITIS; REVIEW; SEPSIS; STAPHYLOCOCCUS AUREUS; WOUND IRRIGATION; ARTICLE; BACTERIAL STRAIN; BLOOD CELL COUNT; CONTROLLED STUDY; DISEASE SEVERITY; LEUKOCYTE DIFFERENTIAL COUNT;

EID: 84864390222     PISSN: None     EISSN: 2000625X     Source Type: Journal    
DOI: 10.3402/dfa.v3i0.18656     Document Type: Review

References (35)

1. Sociedade Brasileira de Diabetes. Diagnostico e classificacão de DM e tratamento de DM tipo 2. Available from: http://www.diabetes.org.br [cited 15 March 2012].
2. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004; 27: 1047-1053.
3. Malerbi DA, Franco LJ. Multicenter study of the prevalence of diabetes mellitus and impaired glucose tolerance in the urban Brazilian population aged 30-69 yr. The Brazilian Cooperative Group on the Study of Diabetes prevalence. Diabetes Care 1992; 15: 1509-1516.
4. Torquato MTCG, Montenegro RN, Jr., Viana LAL, Sousa RAHG, Ianna CMM, Lucas JCB, et al. Prevalence of diabetes mellitus and impaired glucosetolerance in the urban population aged 30-69 years in Ribeirao Preto (Sao Paulo), Brazil. Sao Paulo Med J 2003; 121: 224-230.
5. Sistema de cadastramento e acompanhamento de hipertensos e diabeticos - RN. Available from: http://tabnet.datasus.govbr/cgi/deftohtm.exe?hiperdia/cnv/hdrn.def [cited 22 November 2011].
6. Gamba MA. Lower extremity amputations in patients with diabetes: should be preventable? Acta Paul Enferm 1998; 11: 92-100.
7. Boulton AJM, Pedrosa HC, Macedo GC, Ribeiro JF. Aborda-gem cĺi{dotless}nica e terapeutica do pe diabetico. In: Vilar L, ed. Endocrinologia cĺi{dotless}nica. 3rd ed. Rio de Janeiro: Guanabara Koogan; 2006, pp. 683-699.
8. Boulton AJ. Lowering the risk of neuropathy, foot ulcers and amputations. Diabet Med 1998; 15: S57-S59.
9. Wagner FW, Jr. Treatment of the diabetic foot. Compr Ther 1984; 10: 29-38.
10. Lipsky BA, Berendt AR, Deery HG, Embil JM, Joseph WS, Karchmer AW, et al. Infectious Diseases Society of America. Diagnosis and treatment of diabetic foot infections. Plast Reconstr Surg 2006; 117: S212-S238.
11. Goldstein EJ, Citron DM, Nesbit CA. Diabetic foot infections. Bacteriology and activity of 10 oral antimicrobial agents against bacteria isolated from consecutive cases. Diabetes Care 1996; 19: 638-641.
12. Martinez JL, Baquero F, Andersson DI. Predicting antibiotic resistance. Nat Rev Microbiol 2007; 5: 958-965.
13. Hartemann-Heurtier A, Robert J, Jacqueminet S, Ha Van G, Golmard JL, Jarlier V, et al. Diabetic foot ulcer and multidrug-resistant organisms: risk factors and impact. Diabet Med 2004; 21: 710-715.
14. Aragao ML, Fernandes VO, Quidute ARP, Sales APAM, Dantas FCM, Porto LB, et al. Microbiological profile and clinical outcome of severe foot ulcers of diabetic inpatients. RBPS Fortaleza 2010; 23: 231-236.
15. McCabe CJ, Stevenson RC, Dolan AM. Evaluation of a diabetic foot screening and protection programme. Diabet Med 1998; 15: 80-84.
16. Inderlied CB, Salfinger M. Antimicrobial agents and susceptibility testing: mycobacteria. In: Murray PR, Baron EJ, Pfaller MA, Tenover FC, Yolken RH, eds. Manual of clinical microbiology, 7th ed. Washington, DC: ASM Press; 1999, pp. 1601-1623.
17. Clinical and Laboratory Standards Institute. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard. 8th ed. Wayne, PA: Clinical and Laboratory Standards Institute; 2009, pp. M07-A8.
18. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing; approved standard. 9th ed. Wayne, PA: Clinical and Laboratory Standards Institute; 2009, pp. M100-S19.
19. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. 7th ed. Wayne, PA: Clinical and Laboratory Standards Institute; 2010, pp. M100-S117.
20. Carvalho CB, Neto RM, Aragao LP, Oliveira MM, Nogueira MB, Forti AC. Diabetic foot infection. Bacteriologic analysis of 141 patients. Arq Bras Endocrinol Metabol 2004; 48: 398-405.
21. Grupo de Trabalho Internacional sobre Pe Diabetico. Consenso internacional sobre pe diabetico. Braśi{dotless}lia: Secretaria de Estado de Saude do Distrito Federal; 2001, p. 55.
22. Johnson S, Lebahn F, Peterson LR, Gerding DN. Use of anaerobic collection and transport swab device to recover anaerobic bacteria from infected foot ulcers in diabetics. Clin Infect Dis 1995; 20: S289-S290.
23. Sapico FL, Witte JL, Canawati HN, Montgomerie JZ, Bessman AN. The infected foot of the diabetic patient: quantitative microbiology and analysis of clinical features. Rev Infect Dis 1984; 6: S171-S176.
24. Wheat LJ, Allen SD, Henry M, Kernek CB, Siders JA, Kuebler T, et al. Diabetic foot infections. Bacteriologic analysis. Arch Intern Med 1986; 146: 1935-1940.
25. Pfaller MA, Jones RN, Doern GV, Sader HS, Kugler KC, Beach ML. Survey of blood stream infections attributable to gram-positive cocci: frequency of occurrence and antimicrobial susceptibility of isolates collected in 1997 in the United States, Canada, and Latin America from the SENTRY Antimicrobial Surveillance Program. SENTRY Participants Group. Diagn Microbiol Infect Dis 1997; 33: 283-297.
26. Voss A, Doebbeling BN The worldwide prevalence of methicillin-resistant Staphylococcus aureus. Int J Antimicrob Agents 1995; 5: 101-106.
27. Bergogne-Berezin E, Towner KJ. Acinetobacter spp. as nosocomial pathogens: microbiological, clinical and epidemiologic features. Clin Microbiol Rev 1996; 9: 148-165.
28. Dijkshoorn L, Nemec A, Seifert H. An increasing threat in hospitals: multidrug-resistant Acinetobacter baumannii. Nat Rev Microbiol 2007; 5: 939-951.
29. Karageorgopoulos DE, Falagas ME. Current control and treatment of multidrug-resistant Acinetobacter baumannii infections. Lancet Infect Dis 2008; 8: 751-762.
30. Zubair M, Malik A, Ahmad J. Clinico-microbiological study and antimicrobial drug resistance profile of diabetic foot infections in North India. Foot (Edinb) 2011; 21: 6-14.
31. Liu WZ, Wang AJ, Sun D, Ren NQ, Zhang YQ. Bio-community analysis during the anode biofilm reformation in a two-chamber microbial electrolysis cell (MEC) for H2 production. J Biotech-nol 2010; 150: S1-S576.
32. Stewart PS, Costerton JW Antibiotic resistance of bacteria in biofilms. Lancet 2001; 358: 135-138.
33. Tan H, Peng Z, Li Q, Xu X, Guo S, Tang T. The use of quaternised chitosan-loaded PMMA to inhibit biofilm formation and downregulate the virulence-associated gene expression of antibiotic-resistant staphylococcus. Biomaterials 2012; 33: 365-377.
34. Hart CA, Kariuki S. Antimicrobial resistance in developing countries. BMJ 1998; 317: 647-650.
35. Motta RN, Oliveira MM, Magalhaes PS, Dias AM, Aragao LP, Forti AC, et al. Plasmid-mediated extended-spectrum beta-lactamase-producing strains of Enterobacteriaceae isolated from diabetes foot infections in a Brazilian diabetic center. Braz J Infect Dis 2003; 7: 129-134.